Welcome to EQUITY DEVELOPMENT

The UK's longest established regulated provider of sponsored equity research.

We launched EQUITY DEVELOPMENT in 1997 becoming the first ever  regulated provider of Sponsored Equity Research in the UK.

Our research teams are made up of expert analysts with deep understanding & experience in their sectors.  Our research is distributed to all relevant investment classes & commentators. (at no cost to the reader).

We have made our name by specialising in those companies who are not receiving the attention that they merit, using detailed commentary, appropriate valuation metrics and regular publications to help eradicate undervaluation in the medium term.

 

FREE REGISTRATION

Sign up today and access the very latest company research

LOG IN

For access to all company research please

Healthcare Locums

Healthcare Locums (HLO) is an established provider of specialist staff to the health and social care sectors.

Trading update affirms a genuine special situation among challenged recruitment shares

28% growth in net fee income over three months

All 3 UK divisions experiencing increasing demand

Forecasts upgraded

Publication Date:
July 16 2008

Value Delivery Gathers Pace

Results show execution of strategy on track

With investments made focus now on cash generation and shareholder returns

Market leader in 3 core markets that are both  defensive and growing

Positive trading start in 2008, and further director share purchases

Fair value / share seen conservatively at 150p as EPS and PER improve

Publication Date:
April 25 2008

Trading Update

All divisions experiencing strong demand

Directors increased stake

2008 PE of only 6.5 times

Publication Date:
January 30 2008

Material cluster buy by Directors

Successful placing to cover deferred acquisition consideration  

Nestor's woes present buying opportunity for Directors

Publication Date:
November 27 2007

Results show strategy working

Strong interim results show robust demand for healthcare professionals

Group well positioned after bold acquisition strategy

Further organic growth expected in a market favoured by demographics

2008 projections increased

8.6x PER 2008 leaves significant upside to fair value seen at  150p / share

Publication Date:
October 11 2007

next